Study highlights the ability of the Vaxzevria vaccine in inducing robust mucosal antibody responses, especially in COVID-19-recovered individuals, showcasing a notable defense against various SARS-CoV-2 variants. However, it emphasizes the need for booster doses to enhance anti-SARS-CoV-2 mucosal immunity, especially in infection-naïve individuals, to broaden protection against emerging viral variants.
Patients, doctors press FTC to beef up hospital merger scrutiny
Comments to antitrust regulators lay bare Americans’ anger and disillusionment over consolidation’s effects on all sectors of the economy, but especially health care. A 24-year-old
September 18, 2023